| 7.755 0.605 (8.46%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.28 | 1-year : | 10.84 |
| Resists | First : | 7.94 | Second : | 9.28 |
| Pivot price | 7.39 |
|||
| Supports | First : | 6.89 | Second : | 6.23 |
| MAs | MA(5) : | 7.41 |
MA(20) : | 7.2 |
| MA(100) : | 6.42 |
MA(250) : | 6.87  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 58.8 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 11.4 | Low : | 4.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SGMT ] has closed below upper band by 21.4%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.84 - 7.89 | 7.89 - 7.93 |
| Low: | 7.01 - 7.07 | 7.07 - 7.11 |
| Close: | 7.68 - 7.77 | 7.77 - 7.84 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Mon, 13 Jul 2026
Sagimet Biosciences Inc. Series A Q1 2026 Earnings: Narrower-than-Expected Loss as EPS Surprises Positively - Net Profit Margin - DonanımHaber
Mon, 29 Jun 2026
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com
Mon, 29 Jun 2026
Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com
Mon, 29 Jun 2026
Sagimet lands in Russell indexes as acne drug trial looms - Stock Titan
Sun, 28 Jun 2026
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 21.9 (%) |
| Shares Short | 8,250 (K) |
| Shares Short P.Month | 4,800 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -36.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -5.75 |
| PEG Ratio | 0 |
| Price to Book value | 2.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|